期刊
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
卷 78, 期 3, 页码 282-286出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2013.11.023
关键词
Shigella; Antimicrobial resistance
资金
- Mega-projects of Science and Technology Research of China [2012ZX10004215-003]
- Sub-project 6 of the Sino-US EID (Emerging Infectious Diseases) Cooperation Project
- China Postdoctoral Science Foundation [2012 T50419, 2011 M500781]
A retrospective study conducted on patients with diarrhea in Shanghai, China from 2004-2011, indicated that of 77,600 samples collected, 1,635 (2.1%) tested positive for Shigella. Species isolated included S. sonnei (1,066, 65.1%), S. flexneri (569,34.7%), and S. boydii (3, 0.2%). Most of the Shigella isolates were found to be resistant to streptomycin (98.7%), trimethoprim (98.0%), ampicillin (92.1%), and nalidixic acid (91.7%). Additionally, many isolates were resistant to tetracycline (86.9%), trimethoprim + sulfamethoxazole (80.1%), sulfisoxazole (76.8%) and gentamicin (55.5%). Approximately 80% of the isolates were resistant to at least eight antimicrobial agents, 14% to at least ten antimicrobials tested and 10 isolates to fourteen antimicrobials, including sulfonamides, fluoroquinolones, tetracyclines, aminoglycosides and 13-lactamases. Importantly, coresistance to fluoroquinolones and the third- and fourth-generation cephalosporins was also identified. The high levels of resistance to antimicrobial agents commonly used in clinical medicine presents a great challenge to treating patients with shigellosis. (C) 2014 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据